# EDGAR Filing Document

**Accession Number:** 0001810560
**File Stem:** 0001193125-26-042685
**Filing Date:** 2026-2
**Character Count:** 2416
**Document Hash:** fd906b3fa6ee6060bc5691247ae6da57
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-042685.hdr.sgml**: 20260429

**ACCESSION NUMBER**: 0001193125-26-042685

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260209

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** REVELATION BIOSCIENCES, INC.
- **CENTRAL INDEX KEY:** 0001810560
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 843898466
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 4660 LAJOLLA VILLAGE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122
- **BUSINESS PHONE:** 650-800-3717

**MAIL ADDRESS:**
- **STREET 1:** 4660 LAJOLLA VILLAGE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Petra Acquisition Inc.
- **DATE OF NAME CHANGE:** 20200423

**Revelation Biosciences, Inc.**

**4660 La Jolla Village Drive, Suite 100**

**San Diego, California 92122**

February 9, 2026

**VIA EDGAR AND E-MAIL**

Mr. Chris Edwards

Office of Life Sciences

Division of Corporate Finance

U.S. Securities and Exchange Commission

100 F Street, NE

Washington, DC 20549-7010

---

| | |
|:---|:---|
| Re: | Revelation Biosciences, Inc. |
|  | Registration Statement on Form S-3 |
|  | Commission File No. 333-293078 |

---

Dear Mr. Edwards:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Revelation Biosciences Inc. (the "Company") hereby requests that the effectiveness of the Company's Registration Statement on Form S-3 (File No. 333-293078) be accelerated by the U.S. Securities and Exchange Commission to 4:00 p.m. Eastern Time on Wednesday, February 11, 2026 or as soon thereafter is practicable.

The Company hereby authorizes Joseph P. Galda of J.P. Galda & Co. to orally modify or withdraw this request for acceleration. Please contact Mr. Galda at (215) 815-1534 with any questions you may have concerning this request, and please notify him when this request for acceleration has been granted.

Thank you for your courtesy and cooperation in this matter.

---

| |
|:---|
| Very truly yours, |
| Revelation Biosciences, Inc. |
| <u>/s/ Chester S. Zygmont, III</u> |
| Chief Financial Officer |

---

------